# A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

> **NCT00994175** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 15 (actual)

## Conditions studied

- Severe, Refractory Asthma
- Airway Inflammation
- Airflow Obstruction

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00994175
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-23
- **Primary completion:** 2016-06-24
- **Final completion:** 2016-06-24
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994175, "A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00994175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*